Supplement PD-L1 Immunohistochemistry (IHC) with the most complete evidence to evaluate cancer immune set points1
Peer-reviewed literature demonstrates the need to answer the following critical questions:
- Can the tumor be recognized as “non-self” by the immune system?
- Is the immune response inflamed or suppressed?
- Are the immune cells exhausted or hyper-exhausted?
- Is the tumor immune excluded?
The peer-reviewed literature would support that additional biomarkers influence the response to CPIs:
Only Immune Report Card is designed to provide all the relevant information for clinicians to choose appropriate immunotherapies with an emphasis on checkpoint inhibitors
Specifically, IRC uses five test modes:
- RNA-seq to quantitatively measure transcript levels of 43 genes related to T-cell receptor signaling or other components of the immune cycle and 11 genes related to tumor infiltrating lymphocytes
- DNA-seq to estimate mutational burden
- MSI-PCR to assess microsatellite instability
- Fluorescent in situ hybridization (FISH) to detect copy number gain of PD-L1 and PD-L2
- Immunohistochemistry (IHC) FDA-Approved IHC assays to measure expression of PDL1 and our New York State CLEP approved test for CD3 and CD8 expression and exclusion patterns
IRC uses a synoptic report style to assemble genomic, transcriptomic and protein expression results in a fashion that allows for accurate interpretation and supports clinical decision making for selecting immunotherapies
1. Chen, Daniel S., and Ira Mellman. “Elements of Cancer Immunity and the Cancer Immune Set Point.” Nature 541.7637 (2017): 321-30. Web.
Receive updates about Immune Report Card